Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD +8.48%21 Debt-to-EBITDA is 1.64 as of Sep. 2025, which is 100% above its 10-year median of 0.82. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 90 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 81.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cellyan Biotechnology Co's Debt-to-EBITDA or its related term are showing as below:
HKPD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.39 Med: 0.82 Max: 5.27
Current: 5.27
During the past 3 years, the highest Debt-to-EBITDA Ratio of Cellyan Biotechnology Co was 5.27. The lowest was 0.39. And the median was 0.82.
HKPD's Debt-to-EBITDA is ranked worse than 81.11% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs HKPD: 5.27
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cellyan Biotechnology Co Debt-to-EBITDA Related Terms
Cellyan Biotechnology Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKPD vs MEDS, COSM, SNYR: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Sep. 2025) EBITDA data.
Cellyan Biotechnology Co (HKPD) has a Debt-to-EBITDA of 1.64 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cellyan Biotechnology Co. This is 100% above median its historical median of 0.82. Over the past decade, Cellyan Biotechnology Co's Debt-to-EBITDA has ranged from 0.39 to 5.27. According to the industry distribution chart, Cellyan Biotechnology Co ranks #73 out of 90 companies in the Medical Distribution industry, placing it in the top 81.1%.
Is Cellyan Biotechnology Co's Debt-to-EBITDA too high?
Cellyan Biotechnology Co's current Debt-to-EBITDA of 1.64 is 100% above median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 5.27. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Cellyan Biotechnology Co's value of 1.64 is 33.1% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #73 out of 90 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Debt-to-EBITDA compare to MEDS and COSM?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #73 out of 90 companies for Debt-to-EBITDA. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. Cellyan Biotechnology Co's value of 1.64 is 33.1% below this benchmark. Historically, Cellyan Biotechnology Co's own Debt-to-EBITDA has ranged from 0.39 to 5.27 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 2.45, Cellyan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Debt-to-EBITDA of 1.64 is 33.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cellyan Biotechnology Co. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Debt-to-EBITDA is 1.64, which is 100% above median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Debt-to-EBITDA of 1.64. The current Debt-to-EBITDA is 1.64, which is 100% above median its 10-year median of 0.82 and 33.1% below the Medical Distribution industry median of 2.45. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Debt-to-EBITDA is 1.64 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
